Sapient’s technology characterizes favorable interactions of Lpath’s anti-S1P therapeutic antibody with its target.
Sapient Discovery and Lpath reported the successful completion of a study to assess Lpath’s agent to treat cancer and various ocular diseases. The collaboration used Sapient Discovery’s computational platform to understand the binding properties of Lpath’s humanized sphingomab antibody to its target, sphingosine-1-phosphate (S1P).
“Sapient Discovery’s proprietary Genes-to-Leads technology created dynamic 3-D structural models of the binding of Sphingomab to S1P,” explains Kal Ramnarayan Ph.D., president and CSO of Sapient Discovery, “This has provided valuable insights for the Lpath research team with significant efficiency and cost savings to Lpath.”
Lpath says it is the first to generate therapeutic Mabs against S1P, a bioactive lipid involved in angiogenesis and the progression of cancer.